New book by Larry Connors Click here Improve your trading - See how
With a tradition of over three hundred years, Merck KGaA is one of the oldest pharmaceutical and chemical companies in the world. Merck has 192 companies in 60 countries, which employ over 30,000 personnel worldwide. Merck has focused its corporate headquarters and research & development in Darmstadt, Germany. However, it also operates important research sites in France, Spain, Switzerland, the UK, the US and Japan.
Merck's pharmaceutical operations are divided into the Merck Serono business and Consumer Health Care. For the former, research and marketing efforts are centred on two key therapeutic areas, namely CardioMetabolic Care and Oncology.
Integration of Serono into what was previously the Ethicals Division to form Merck Serono was completed in September 2007. The acquisition took place in January 2007 and the merger created a combined business with strong capabilities, especially in neurology and oncology.
Merck is continuing to focus on drugs for which there is high unmet need, specifically in the fields of CardioMetabolic Care, Oncology and, following the acquisition of Serono, Reproductive Health, Neurology and Autoimmune & Inflammatory. In 2007, Erbitux, Rebif and the Concor/bisoprolol products were top selling constituents of the Merck Serono product portfolio.
The acquisition of Serono fulfils, in part, Merck group plans to increase its pharma presence in the US in terms of research, development and commercialisation and brings with it a substantial basic research capability, together with an appropriately sized drug-development organisation and then the necessary commercial capabilities to allow for direct marketing and sales.
This new strategic analysis report Merck KGaA: Pipeline - Products - Performance - Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. These reports are updated with the latest data on a continuing basis and the full report is released quarterly. Once a year the report undergoes a major review in line with the company's year end. Buyers of the print/pdf editions will receive the latest version and quarterly updated reports for a year. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Some of the Companies mentioned:
- Abbott
- AEterna Zentaris
- Alkermes Inc
- Biomira Inc
- Celgene Corporation
- Dainippon Sumitomo Pharma
- Eli Lilly
- Gene Logic Inc
- Immunicon Corporation
- IVAX Corporation
- KineMed Inc
- NovImmune
- Organon
- Paratek Pharmaceuticals Inc
- Pfizer
- Takeda
- TargeGen Inc
- Vernalis
- Wyeth/Columbia Laboratories Inc
- ZymoGenetics Inc
For more information visit http://www.researchandmarkets.com/research/5f8df3/merck_kgaa_pipeli
Source: Espicom Business Intelligence Ltd
CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (from USA) Fax: +353 1 481 1716 (rest of the world) e-mail: press@researchandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
